85. 特発性間質性肺炎 Idiopathic interstitial pneumonia Clinical trials / Disease details
臨床試験数 : 627 / 薬物数 : 443 - (DrugBank : 120) / 標的遺伝子数 : 99 - 標的パスウェイ数 : 212
Showing 1 to 10 of 17 diseases
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2009-011169-98-CZ (EUCTR) | 10/01/2011 | 29/11/2010 | ARTEMIS-PH: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group Study to Evaluate the Efficacy and Safety of Ambrisentan in Subjects with Idiopathic Pulmonary Fibrosis and Pulmonary Hypertension - ARTEMIS-PH ARTEMIS-PH: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group St ... | ARTEMIS-PH: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group Study to Evaluate the Efficacy and Safety of Ambrisentan in Subjects with Idiopathic Pulmonary Fibrosis and Pulmonary Hypertension - ARTEMIS-PH ARTEMIS-PH: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group St ... | Pulmonary Hypertension associated with Idiopathic Pulmonary Fibrosis MedDRA version: 12.1;Level: LLT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis MedDRA version: 12.1;Classification code 10037400;Term: Pulmonary hypertension Pulmonary Hypertension associated with Idiopathic Pulmonary Fibrosis MedDRA version: 12.1;Level: LLT ... | Trade Name: Letairis INN or Proposed INN: Ambrisentan Trade Name: Letairis INN or Proposed INN: Ambrisentan Trade Name: Letairis INN or Proposed INN: Ambrisentan Trade Name: Letairis INN or Proposed INN: Ambrise ... | Gilead Sciences, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 225 | Phase 3 | United Kingdom;Germany;Czech Republic;Italy;Austria | ||
| 2 | EUCTR2008-004405-34-CZ (EUCTR) | 13/09/2010 | 07/01/2009 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group, Event-Driven Study to Evaluate the Efficacy and Safety of Ambrisentan in Subjects with Early Idiopathic Pulmonary Fibrosis (IPF) - ARTEMIS-IPF A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group, Event-Driven ... | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group, Event-Driven Study to Evaluate the Efficacy and Safety of Ambrisentan in Subjects with Early Idiopathic Pulmonary Fibrosis (IPF) - ARTEMIS-IPF A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group, Event-Driven ... | Idiopathic pulmonary fibrosis (IPF) MedDRA version: 9.1;Level: LLT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis Idiopathic pulmonary fibrosis (IPF) MedDRA version: 9.1;Level: LLT;Classification code 10021240;Term ... | Trade Name: Letairis 5 mg INN or Proposed INN: Ambrisentan Trade Name: Letairis 10 mg INN or Proposed INN: Ambrisentan Trade Name: Letairis5 mg INN or Proposed INN: Ambrisentan Trade Name: Letairis10 mg INN or Proposed INN ... | Gilead Sciences Incorporated | NULL | Not Recruiting | Female: yes Male: yes | 660 | Phase 3 | United Kingdom;Germany;Czech Republic;Netherlands;Belgium;France;Spain;Ireland;Italy;Austria | ||
| 3 | EUCTR2009-011169-98-AT (EUCTR) | 26/11/2009 | 25/08/2009 | ARTEMIS-PH: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group Study to Evaluate the Efficacy and Safety of Ambrisentan in Subjects with Idiopathic Pulmonary Fibrosis and Pulmonary Hypertension - ARTEMIS-PH ARTEMIS-PH: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group St ... | ARTEMIS-PH: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group Study to Evaluate the Efficacy and Safety of Ambrisentan in Subjects with Idiopathic Pulmonary Fibrosis and Pulmonary Hypertension - ARTEMIS-PH ARTEMIS-PH: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group St ... | Pulmonary Hypertension associated with Idiopathic Pulmonary Fibrosis MedDRA version: 12.0;Level: LLT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis MedDRA version: 12.0;Classification code 10037400;Term: Pulmonary hypertension Pulmonary Hypertension associated with Idiopathic Pulmonary Fibrosis MedDRA version: 12.0;Level: LLT ... | Trade Name: Letairis INN or Proposed INN: Ambrisentan Trade Name: Letairis INN or Proposed INN: Ambrisentan Trade Name: Letairis INN or Proposed INN: Ambrisentan Trade Name: Letairis INN or Proposed INN: Ambrise ... | Gilead Sciences, Inc | NULL | Not Recruiting | Female: yes Male: yes | 225 | Phase 3 | Czech Republic;United Kingdom;Germany;Italy;Austria | ||
| 4 | EUCTR2009-011169-98-DE (EUCTR) | 03/11/2009 | 06/08/2009 | ARTEMIS-PH: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group Study to Evaluate the Efficacy and Safety of Ambrisentan in Subjects with Idiopathic Pulmonary Fibrosis and Pulmonary Hypertension - ARTEMIS-PH ARTEMIS-PH: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group St ... | ARTEMIS-PH: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group Study to Evaluate the Efficacy and Safety of Ambrisentan in Subjects with Idiopathic Pulmonary Fibrosis and Pulmonary Hypertension - ARTEMIS-PH ARTEMIS-PH: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group St ... | Pulmonary Hypertension associated with Idiopathic Pulmonary Fibrosis MedDRA version: 12.0;Level: LLT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis MedDRA version: 12.0;Classification code 10037400;Term: Pulmonary hypertension Pulmonary Hypertension associated with Idiopathic Pulmonary Fibrosis MedDRA version: 12.0;Level: LLT ... | Trade Name: Letairis INN or Proposed INN: Ambrisentan Trade Name: Letairis INN or Proposed INN: Ambrisentan Trade Name: Letairis INN or Proposed INN: Ambrisentan Trade Name: Letairis INN or Proposed INN: Ambrise ... | Gilead Sciences, Inc | NULL | Not Recruiting | Female: yes Male: yes | 225 | Phase 3 | Czech Republic;United Kingdom;Germany;Italy;Austria | ||
| 5 | EUCTR2009-011169-98-GB (EUCTR) | 30/10/2009 | 01/09/2009 | ARTEMIS-PH: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group Study to Evaluate the Efficacy and Safety of Ambrisentan in Subjects with Idiopathic Pulmonary Fibrosis and Pulmonary Hypertension - ARTEMIS-PH ARTEMIS-PH: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group St ... | ARTEMIS-PH: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group Study to Evaluate the Efficacy and Safety of Ambrisentan in Subjects with Idiopathic Pulmonary Fibrosis and Pulmonary Hypertension - ARTEMIS-PH ARTEMIS-PH: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group St ... | Pulmonary Hypertension associated with Idiopathic Pulmonary Fibrosis MedDRA version: 12.0;Level: LLT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis MedDRA version: 12.0;Classification code 10037400;Term: Pulmonary hypertension Pulmonary Hypertension associated with Idiopathic Pulmonary Fibrosis MedDRA version: 12.0;Level: LLT ... | Trade Name: Letairis INN or Proposed INN: Ambrisentan Trade Name: Letairis INN or Proposed INN: Ambrisentan Trade Name: Letairis INN or Proposed INN: Ambrisentan Trade Name: Letairis INN or Proposed INN: Ambrise ... | Gilead Sciences, Inc | NULL | Not Recruiting | Female: yes Male: yes | 225 | Phase 3 | Czech Republic;Germany;United Kingdom;Italy;Austria | ||
| 6 | EUCTR2009-011169-98-IT (EUCTR) | 22/09/2009 | 21/09/2009 | A Phase 3, Randomized, Double Blind, Placebo Controlled, Multi Center, Parallel Group Study to Evaluate the Efficacy and Safety of Ambrisentan in Subjects with Idiopathic Pulmonary Fibrosis and Pulmonary Hypertension - ND A Phase 3, Randomized, Double Blind, Placebo Controlled, Multi Center, Parallel Group Study to Evalu ... | A Phase 3, Randomized, Double Blind, Placebo Controlled, Multi Center, Parallel Group Study to Evaluate the Efficacy and Safety of Ambrisentan in Subjects with Idiopathic Pulmonary Fibrosis and Pulmonary Hypertension - ND A Phase 3, Randomized, Double Blind, Placebo Controlled, Multi Center, Parallel Group Study to Evalu ... | Idiopathic Pulmonary Fibrosis and Pulmonary Hypertension MedDRA version: 9.1;Level: LLT;Classification code 10021240 MedDRA version: 9.1;Classification code 10037400 Idiopathic Pulmonary Fibrosis and Pulmonary Hypertension MedDRA version: 9.1;Level: LLT;Classificati ... | Trade Name: Letairis Trade Name: Letairis | Gilead Sciences Incorporated | NULL | Not Recruiting | Female: yes Male: yes | 225 | Phase 3 | Czech Republic;United Kingdom;Germany;Italy;Austria | ||
| 7 | EUCTR2008-004405-34-IE (EUCTR) | 08/09/2009 | 07/01/2009 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group, Event-Driven Study to Evaluate the Efficacy and Safety of Ambrisentan in Subjects with Idiopathic Pulmonary Fibrosis (IPF) - ARTEMIS A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group, Event-Driven ... | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group, Event-Driven Study to Evaluate the Efficacy and Safety of Ambrisentan in Subjects with Idiopathic Pulmonary Fibrosis (IPF) - ARTEMIS A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group, Event-Driven ... | Idiopathic pulmonary fibrosis (IPF) MedDRA version: 9.1;Level: LLT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis Idiopathic pulmonary fibrosis (IPF) MedDRA version: 9.1;Level: LLT;Classification code 10021240;Term ... | Trade Name: Letairis 5 mg INN or Proposed INN: Ambrisentan Trade Name: Letairis 10 mg INN or Proposed INN: Ambrisentan Trade Name: Letairis5 mg INN or Proposed INN: Ambrisentan Trade Name: Letairis10 mg INN or Proposed INN ... | Gilead Sciences Incorporated | NULL | Not Recruiting | Female: yes Male: yes | 600 | Phase 3 | United Kingdom;Germany;Czech Republic;Netherlands;Belgium;France;Spain;Ireland;Italy;Austria | ||
| 8 | EUCTR2008-004405-34-IT (EUCTR) | 03/08/2009 | 27/07/2009 | A Phase 3, Randomized, Double-blind, Placebo-controlled, Multi-Center, Parallel-Group, Event-Driven Study to Evaluate the Efficacy and Safety of Ambrisentan in subjects with Early Idiopathic Pulmonary Fibrosis (IPF) - ARTEMIS-IPF A Phase 3, Randomized, Double-blind, Placebo-controlled, Multi-Center, Parallel-Group, Event-Driven ... | A Phase 3, Randomized, Double-blind, Placebo-controlled, Multi-Center, Parallel-Group, Event-Driven Study to Evaluate the Efficacy and Safety of Ambrisentan in subjects with Early Idiopathic Pulmonary Fibrosis (IPF) - ARTEMIS-IPF A Phase 3, Randomized, Double-blind, Placebo-controlled, Multi-Center, Parallel-Group, Event-Driven ... | Idiopathic pulmonary fibrosis MedDRA version: 12.0;Level: LLT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis Idiopathic pulmonary fibrosis MedDRA version: 12.0;Level: LLT;Classification code 10021240;Term: Idi ... | Trade Name: VOLIBRIS INN or Proposed INN: Ambrisentan Trade Name: VOLIBRIS INN or Proposed INN: Ambrisentan Trade Name: VOLIBRIS INN or Proposed INN: Ambrisentan Trade Name: VOLIBRIS INN or Proposed INN: Ambrise ... | Gilead Sciences Incorporated | NULL | Not Recruiting | Female: yes Male: yes | 600 | Phase 3 | United Kingdom;Germany;Czech Republic;Netherlands;Belgium;France;Spain;Ireland;Italy;Austria | ||
| 9 | NCT00879229 (ClinicalTrials.gov) | July 2009 | 8/4/2009 | ARTEMIS-PH - Study of Ambrisentan in Subjects With Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis ARTEMIS-PH - Study of Ambrisentanin Subjects With Pulmonary Hypertension Associated With Idiopathic ... | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group Study to Evaluate the Efficacy and Safety of Ambrisentan in Subjects With Idiopathic Pulmonary Fibrosis and Pulmonary Hypertension A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group Study to Evalu ... | Idiopathic Pulmonary Fibrosis;Pulmonary Hypertension | Drug: Ambrisentan;Drug: Placebo | Gilead Sciences | NULL | Terminated | 35 Years | 80 Years | All | 40 | Phase 3 | United States;Australia;Austria;Canada;Germany;Italy;United Kingdom;Belgium;Ireland;Israel |
| 10 | EUCTR2008-004405-34-GB (EUCTR) | 08/06/2009 | 28/04/2009 | ARTEMIS-IPF: A Phase 3, Randomized, Double Blind, Placebo Controlled, Multi Center, Parallel Group, Event Driven Study to Evaluate the Efficacy and Safety of Ambrisentan in Subjects with Early Idiopathic Pulmonary Fibrosis (IPF) - ARTEMIS-IPF ARTEMIS-IPF: A Phase 3, Randomized, Double Blind, Placebo Controlled, Multi Center, Parallel Group, ... | ARTEMIS-IPF: A Phase 3, Randomized, Double Blind, Placebo Controlled, Multi Center, Parallel Group, Event Driven Study to Evaluate the Efficacy and Safety of Ambrisentan in Subjects with Early Idiopathic Pulmonary Fibrosis (IPF) - ARTEMIS-IPF ARTEMIS-IPF: A Phase 3, Randomized, Double Blind, Placebo Controlled, Multi Center, Parallel Group, ... | Idiopathic pulmonary fibrosis (IPF) MedDRA version: 9.1;Level: LLT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis Idiopathic pulmonary fibrosis (IPF) MedDRA version: 9.1;Level: LLT;Classification code 10021240;Term ... | Trade Name: Letairis 5 mg INN or Proposed INN: Ambrisentan Trade Name: Letairis 10 mg INN or Proposed INN: Ambrisentan Trade Name: Letairis5 mg INN or Proposed INN: Ambrisentan Trade Name: Letairis10 mg INN or Proposed INN ... | Gilead Sciences Incorporated | NULL | Not Recruiting | Female: yes Male: yes | 660 | Phase 3 | Germany;Czech Republic;United Kingdom;Netherlands;Belgium;France;Spain;Ireland;Italy;Austria |